Contact this trialFirst, we need to learn more about you.
Immunotherapy
Durvalumab + Olaparib for Bladder Cancer
Recruiting0 awardsPhase 2
Hamilton, Ontario
This trial tests a combination of two drugs, durvalumab and olaparib, for patients with advanced bladder cancer who can't receive standard chemotherapy. Durvalumab helps the immune system attack cancer, while olaparib makes it harder for cancer cells to repair themselves. The goal is to see if this combination is more effective than using durvalumab alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.